NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. (Q39134413)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 December 2016

Language	Label	Description	Also known as
English	NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.	scientific article published on 2 December 2016

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. (English)

1 reference

Europe PubMed Central

9 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Eiichi Ogawa

1

1 reference

Europe PubMed Central

9 September 2017

Norihiro Furusyo

2

1 reference

Europe PubMed Central

9 September 2017

Hideyuki Nomura

3

1 reference

Europe PubMed Central

9 September 2017

Kazufumi Dohmen

4

1 reference

Europe PubMed Central

9 September 2017

Nobuhiko Higashi

5

1 reference

Europe PubMed Central

9 September 2017

Kazuhiro Takahashi

6

1 reference

Europe PubMed Central

9 September 2017

Akira Kawano

7

1 reference

Europe PubMed Central

9 September 2017

Koichi Azuma

8

1 reference

Europe PubMed Central

9 September 2017

Takeaki Satoh

9

1 reference

Europe PubMed Central

9 September 2017

Makoto Nakamuta

10

1 reference

Europe PubMed Central

9 September 2017

Toshimasa Koyanagi

11

1 reference

Europe PubMed Central

9 September 2017

Masaki Kato

12

1 reference

Europe PubMed Central

9 September 2017

Shinji Shimoda

13

1 reference

Europe PubMed Central

9 September 2017

Eiji Kajiwara

14

1 reference

Europe PubMed Central

9 September 2017

Jun Hayashi

15

1 reference

Europe PubMed Central

9 September 2017

Kyushu University Liver Disease Study (KULDS) Group

16

1 reference

Europe PubMed Central

9 September 2017

publication date

2 December 2016

1 reference

Europe PubMed Central

9 September 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

9 September 2017

52

1 reference

Europe PubMed Central

9 September 2017

7

1 reference

Europe PubMed Central

9 September 2017

845-854

1 reference

Europe PubMed Central

9 September 2017

Changing trends in hepatitis C infection over the past 50 years in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00535-016-1290-1

21 January 2018

FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

1 reference

https://pubmed.ncbi.nlm.nih.gov/27913920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-016-1290-1

1 reference

Europe PubMed Central

9 September 2017

release_ebcmp3bqgrfpblkw4mukhsge2y

1 reference

https://api.fatcat.wiki/v0/release/ebcmp3bqgrfpblkw4mukhsge2y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39134413&oldid=1837582055"